Ultra First (3 weeks) NASH screening mouse model
Physiogenex has developed a method for NASH screening that can be implemented in three weeks. The control drugs are ezetimibe and liraglutide.
A test system has been developed by Physiogenex using a unique method (using cyclodextrin, as described later) that allows for the extremely rapid induction of NASH within just three weeks. This model uses 8-week-old male mice and measures parameters such as ALT, AST, liver weight as a percentage of body weight, total cholesterol, triglycerides, and fatty acids, all of which increase within just three weeks (at 11 weeks of age). It also shows an increase in the NAS score (indicators: steatosis, inflammation, fibrosis, ballooning, total score) and significant liver inflammation and fibrosis. Treatment with ezetimibe (5 mg/kg) for two weeks results in a decrease in plasma total cholesterol and liver fat, a reduction in gene expression related to inflammation and fibrosis, and a lower overall NAFLD score due to decreased liver inflammation. Similarly, treatment with liraglutide for two weeks also shows a reduction in body weight and liver weight, as well as a lower overall NAS score due to decreased liver inflammation. For more details, please contact us. *Inquiries can also be made through our website. We will respond promptly. (Search for "Clea Japan" at http://www.clea-japan.com/)
